ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°.
ΠΠ°ΡΡΡΠ΅Π½ΠΈΡ ΠΏΠ°ΠΌΡΡΠΈ Ρ ΠΏΠΎΠΆΠΈΠ»ΡΡ
Ruther E., Ritter R., Apecechea M. et al. Sustained improvement in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy. //J Neural Transm. -2000. -V.107. -P.815β829. Bars P., Katz M., Berman N., Itil T., Freedman A., Schatzberg A. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. // JAMA. — 1997… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°. ΠΠ°ΡΡΡΠ΅Π½ΠΈΡ ΠΏΠ°ΠΌΡΡΠΈ Ρ ΠΏΠΎΠΆΠΈΠ»ΡΡ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
1. ΠΡΠΊΠ°ΡΠΈΠ½Π° Π. Π., ΠΡΠΈΠ³ΠΎΡΡΠ΅Π²Π° Π. Π., Π‘ΠΎΠΊΠΎΠ»ΡΡΠΈΠΊ Π. Π. ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π°ΠΌΠΈΡΠΈΠ΄ΠΈΠ½Π° Π½Π° ΡΠ°Π½Π½ΠΈΡ ΡΡΠ°ΠΏΠ°Ρ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΠ»ΡΡΠ³Π΅ΠΉΠΌΠ΅ΡΠ°. //Π.Π½Π΅Π²ΡΠΎΠΏΠ°ΡΠΎΠ». ΠΈ ΠΏΡΠΈΡ ΠΈΠ°ΡΡ. -1991. -Π’.91., № 9. -Π‘.53−58.
2. ΠΠ΅ΡΠ΅ΡΠ°Π³ΠΈΠ½ Π. Π., ΠΠ΅Π±Π΅Π΄Π΅Π²Π° Π. Π. ΠΠ΅Π³ΠΊΠΈΠ΅ ΡΠΎΡΠΌΡ ΠΌΡΠ»ΡΡΠΈΠΈΠ½ΡΠ°ΡΠΊΡΠ½ΠΎΠΉ Π΄Π΅ΠΌΠ΅Π½ΡΠΈΠΈ: ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅ΡΠ΅Π±ΡΠΎΠ»ΠΈΠ·ΠΈΠ½Π°. //Π‘ΠΎΠ².ΠΠ΅Π΄. -1991. -β.11. -Π‘.6−8.
3. ΠΡΠΎΠΏΠΏΠ° Π‘. Π. ΠΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½Π°Ρ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΠ»ΡΡΠ³Π΅ΠΉΠΌΠ΅ΡΠ°. //Π ΠΠ΅Π²ΡΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΡΠΈΡ ΠΈΠ°ΡΡΠΈΠΈ. -1991. -Π’.91. -№ 9. -Π‘.110−116.
4. ΠΠ°ΠΌΡΠ»ΠΈΠ½ Π. Π., Π―Ρ Π½ΠΎ Π. Π. Π‘ΠΎΡΡΠ΄ΠΈΡΡΠ°Ρ ΠΌΠΎΠ·Π³ΠΎΠ²Π°Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΠΆΠΈΠ»ΠΎΠ³ΠΎ ΠΈ ΡΡΠ°ΡΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΠΎ-ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅). //Π ΠΠ΅Π²ΡΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΡΠΈΡ ΠΈΠ°ΡΡΠΈΠΈ. -1993. -Π’.93. -N.2. -Π‘.10−13.
5. ΠΠ°Ρ Π°ΡΠΎΠ² Π. Π., ΠΠ°ΠΌΡΠ»ΠΈΠ½ Π. Π. ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Ρ ΠΏΠΎΠΆΠΈΠ»ΡΡ . //ΠΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ. ΠΠΎΠ΄ ΡΠ΅Π΄ Π. Π. Π―Ρ Π½ΠΎ. -ΠΠΎΡΠΊΠ²Π°: ΠΠΠ ΠΈΠΌ. Π. Π. Π‘Π΅ΡΠ΅Π½ΠΎΠ²Π°. -2000.
6. ΠΠ°Ρ Π°ΡΠΎΠ² Π. Π. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠ°Π½Π°ΠΊΠ°Π½Π° Π² Π½Π΅ΠΉΡΠΎΠ³Π΅ΡΠΈΠ°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅. // ΠΠ΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π». -1997. -Π’.5. -Π‘.42−49.
7. ΠΠ°Ρ Π°ΡΠΎΠ² Π. Π., ΠΠ°ΠΌΡΠ»ΠΈΠ½ Π. Π., Π―Ρ Π½ΠΎ Π. Π. ΠΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π΄Π΅ΠΌΠ΅Π½ΡΠΈΠΉ. //ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΡ. -1994. -Π’.3. -№ 4. -Π‘. 69−75.
8. ΠΡΡΠΈΡ Π. Π . ΠΡΡΡΠΈΠ΅ ΠΊΠΎΡΠΊΠΎΠ²ΡΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°. //ΠΠΎΡΠΊΠ²Π°: ΠΈΠ·Π΄-Π²ΠΎ ΠΠΠ£. -1969.
9. ΠΡΡΠΈΡ Π. Π . ΠΡΠ½ΠΎΠ²Ρ Π½Π΅ΠΉΡΠΎΠΏΡΠΈΡ ΠΎΠ»ΠΎΠ³ΠΈΠΈ. //ΠΠΎΡΠΊΠ²Π°: ΠΈΠ·Π΄-Π²ΠΎ ΠΠΠ£. -1973.
10. ΠΡΡΠΈΡ Π. Π . ΠΠ΅ΠΉΡΠΎΠΏΡΠΈΡ ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΏΠ°ΠΌΡΡΠΈ. ΠΠ°ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠ°ΠΌΡΡΠΈ ΠΏΡΠΈ Π»ΠΎΠΊΠ°Π»ΡΠ½ΡΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡΡ ΠΌΠΎΠ·Π³Π°. //ΠΠΎΡΠΊΠ²Π°: ΠΠ΅Π΄Π°Π³ΠΎΠ³ΠΈΠΊΠ°. -1974.
11. ΠΡΡΠΈΡ Π. Π . ΠΠ΅ΠΉΡΠΎΠΏΡΠΈΡ ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΏΠ°ΠΌΡΡΠΈ. ΠΠ°ΡΡΡΠ΅Π½ΠΈΡ ΠΏΠ°ΠΌΡΡΠΈ ΠΏΡΠΈ Π³Π»ΡΠ±ΠΈΠ½Π½ΡΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡΡ ΠΌΠΎΠ·Π³Π°. //ΠΠΎΡΠΊΠ²Π°: ΠΠ΅Π΄Π°Π³ΠΎΠ³ΠΈΠΊΠ°. -1976.
12. ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½Π°Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π±ΠΎΠ»Π΅Π·Π½Π΅ΠΉ ΠΈ ΠΏΡΠΎΠ±Π»Π΅ΠΌ, ΡΠ²ΡΠ·Π°Π½Π½ΡΡ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ΠΌ. ΠΠ΅ΡΡΡΡΠΉ ΠΏΠ΅ΡΠ΅ΡΠΎΡΡ. (ΠΠΠ-10). //-ΠΠ΅Π½Π΅Π²Π°, ΠΠΠ. -1995.
13. Π¨ΠΌΠΈΠ΄Ρ Π. Π. ΠΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΉ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΈ ΡΠΏΠΈΠ½Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°. //Π. ΠΠ΅Π²ΡΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΡΠΈΡ ΠΈΠ°ΡΡΠΈΠΈ. -1985. -Π’.85. -Π‘.192−203.
14. Π―Ρ Π½ΠΎ Π. Π., ΠΠ΅Π²ΠΈΠ½ Π. Π‘., ΠΠ°ΠΌΡΠ»ΠΈΠ½ Π. Π. Π‘ΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΠΠ Π’-Π΄Π°Π½Π½ΡΡ ΠΏΡΠΈ Π΄ΠΈΡΡΠΈΡΠΊΡΠ»ΡΡΠΎΡΠ½ΠΎΠΉ ΡΠ½ΡΠ΅ΡΠ°Π»ΠΎΠΏΠ°ΡΠΈΠΈ. Π‘ΠΎΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ 2: ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ. //ΠΠ΅Π²ΡΠΎΠ».ΠΆΡΡΠ½. -2001. -Π’.6, № 3. -Π‘.10−19.
15. Π―Ρ Π½ΠΎ Π. Π., Π. Π. ΠΠ°ΠΌΡΠ»ΠΈΠ½, Π. Π. ΠΠ°Ρ Π°ΡΠΎΠ², Π. Π‘. ΠΠ΅Π²ΠΈΠ½, Π. Π. ΠΠ»ΠΊΠΈΠ½. ΠΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²ΡΡΠΎΠΊΠΈΡ Π΄ΠΎΠ· ΡΠ΅ΡΠ΅Π±ΡΠΎΠ»ΠΈΠ·ΠΈΠ½Π° ΠΏΡΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ Π΄Π΅ΠΌΠ΅Π½ΡΠΈΠΈ. //Π’Π΅Ρ ΠΡΡ ΠΈΠ². -1996. -Π’.68. -№ 10. -Π‘.65−69.
16. Π―Ρ Π½ΠΎ Π. Π. ΠΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ Π²ΠΎΠΏΡΠΎΡΡ Π½Π΅ΠΉΡΠΎΠ³Π΅ΡΠΈΠ°ΡΡΠΈΠΈ. //Π ΡΠ±. Π. Π. Π―Ρ Π½ΠΎ, Π. Π. ΠΠ°ΠΌΡΠ»ΠΈΠ½ (ΡΠ΅Π΄.): ΠΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ Π² Π½Π΅ΠΉΡΠΎΠ³Π΅ΡΠΈΠ°ΡΡΠΈΠΈ. -ΠΠΎΡΠΊΠ²Π°. -1995. -Π§.1. -Π‘.9−29.
17. Π―Ρ Π½ΠΎ Π. Π., ΠΠ°ΠΌΡΠ»ΠΈΠ½ Π. Π., ΠΠΈΠ±ΠΈΠΊΠΎΠ² Π. Π. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΎΡΡΠ΄ΠΈΡΡΠ°Ρ ΠΌΠΎΠ·Π³ΠΎΠ²Π°Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Ρ ΠΏΠΎΠΆΠΈΠ»ΡΡ : ΠΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΠΎ-ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΡ. //ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π³Π΅ΡΠΎΠ½ΡΠΎΠ»ΠΎΠ³ΠΈΡ. -1995. -N.1. -Π‘.32−36.
18. Albert M.L. Subcortical dementia. In: Alzheimer’s disease: Senile Dementia and Related Disorders. -New York, Raven Press, 1978, V.7, pp 173−180.
19. Amaducci L., L.Andrea. The epidemiology of the dementia in Europe.//In A. Culebras, J. Matias Cuiu, G. Roman (eds): New concepts in vascular dementia. -Barseleona: Prouse Science Publissher. -1993. -P.19−27.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. -Washington: American Psychiatric Association. -1994.
21. Anand R., Hartman R., Gharabawi G. Worldwide clinical experience with Exelon, a new generation of cholinesterase inhibitor in the treatment of Alzheimer’s disease. //Eur J Neurol. -1997. -Vol.4, Suppl.1.-P.S.37.
22. Bae C.Y., Cho C.Y., Cho K. Et al. A double-blind placebo controlled, multicenter study of Cerebrolysin in Alzheimer’s disease. //J Am Geriatr Soc. -2000. -Vol.48. -P.1566−1571.
23. Bars P., Katz M., Berman N., Itil T., Freedman A., Schatzberg A. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. // JAMA. — 1997. -Vol.278, N.16. -P.1327−1332.
24. Bartus R.T. Drug to treat age related neurodegenerative problems. //J Am Ger Soc. -1990. -V.38. -P.680−695.
25. Beatty W.W., N. Butters, D.S.Janowsky. Patterns of memory failure after scopolamine treatment: implication for cholinergic hypotesis of dementia. //Behav Neural Biol. -1986. -V.45. -P.196−211.
26. Becker J.T., F.J.Huff, R.D.Nebes et al. Neuropsychological function in Alzheimer’s disease: pattern of impairment and rates of progression. //Arch Neurol. -1988. -V.45. -№ 3. -P.263−268.
27. Bushke H, E.Grober. Genuine memory deficit in age associated memory impaiment. //Dev Neuropsychol. -1986. -V. 2. -P.287−307.
28. Chrisensen, N. Malty, A.F.Lorn et al. Cholinergic `blocade' as a model of the cognitive deficit in Alheimer’s disease. //Brain. -1992. -V.115. -P.1681−99.
29. Ciocon J.O., J.F.Potter. Age-related changes in human memory: normal and abnormal. //Normal and Abnormal Geriatrics. -1988. -V.43. -N.10.-P.43−48.
30. Claus J.J., C. Ludvig, E. Mohr et al. Nootropic druds in Alzheimer’s disease. //Neurology. -1991. -V.41. -P. 570−574.
31. Crook T. H, R. Bartus, S. Ferris et al. Age Associated memory impairment. Proposed diagnostic criteria and measures of clinical change. //Dev Neuropsychol. -1986. -V.2. -P.261−276.
32. Cummings J.L. Subcortical dementia. //New York: Oxford Press. -1990.
33. Π‘urran H.V. Benzodiazepines, memory and mood: a rewiew. //Psychopharmacology. -1991. -V. 105. -P.1−8.
34. Gauthier S. Results of 6-month randomized placebo-controlled study with Cerebrolysin in Alzheimer’s disease. //Eur J Neurol. -1999. -Vol.6, suppl.3. -P.28.
35. Grober E., H.Bushke. Genuine memory deficit in dementia. //Dev Neuropsychol. -1987. -V.3. -P.13−36.
36. Grober E., H. Bushke, H. Crystal et al. Screening for dementia by memory testing. //Neurology. -1988. -V.38. -P.900−903.
37. Folstein M.F., S.E.Folstein, P.R.McHugh. Mini-Mental State: a practical guidefor grading the mental state of patients for the clinician. //J Psych Res. -1975. -V.12. -P.189−198.
38. Hershey L.A., Olszewski W.A. Ischemic vascular dementia. //In: Handbook of Demented Illnesses. Ed. by J.C.Morris. -New York etc.: Marcel Dekker, Inc. -1994. -P.335−351.
39. Huppert F.A., M.D.Kopellman. Rates of forgetting in normal aging: a comparison with dementia. //Neuropsychology. -1989. -V.27. -№ 6. -P.849−60.
40. Iqbal K., B. Winblad, T. Nishumura,, N. Takeda, H. Wishewski (eds). Alzheimer’s disease: biology, diagnosis and therapeutics. //J.Willey and sons ltd. -1997.
41. Karlsson T., L. Backman, A. Herlitz et al. Memory improvement at different stages of AD. //Neuropsychol. -1989. -V. 27. -№ 5. -P.737−42.
42. Kopelman M.D.and T.H.Corn. Cholinergic `blocade'as a model for cholinergic depletion. //Brain. -1988. -V.111. -P.1079 — 1110.
43. Kopelman M.D. Amnesia: organic and psychogenic. //Br J Psych. -1987. -V.150. -P.428−442.
44. Kopelman M.D. The cholinergic neurotransmitter system in human memory and dementia: a review. //Quart J Exp Psychol. -1986. -V.38. -P.535−573.
45. Kumor V., M.Calach. Treatment of Alzheimer’s disease with cholinergic drugs. //Int J Clin Pharm Ther Toxicol. -1991. -V.29. -№ 1. -P.23−37.
46. Lezak M.D. Neuropsychology assessment. //N.Y. University Press. -1983. -P.768.
47. Lovenstone S., Gauthier S. Management of dementia. London: Martin Dunitz, 2001.
48. McKahn G., D. Drachman, M. Folstein et al. Clinical diagnosis of Alzheimer’s disease: Report of NINCDS ADRDA Work group under the ausices of Department of Health and Human Services Task Force on Alzheimer’s disease. //Neurology. -1984. -V.34. -P.939−944.
49. Perry R., I. McKeith, E.Perry. Dementia with Lewy bodies. clinical, pathological and treatment issues. //Cambridge University Press. -1996. -P.510.
50. Reisberg B., Windscheif U., Ferris S. et al. Memantine in moderately severe to severe Alzheimer’s disease: results of placebo-controlled 6 month trial. //Neurobiol Aging. -2000. -Vol.21. -P.S275.
51. Ruther E., Ritter R., Apecechea M. et al. Sustained improvement in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy. //J Neural Transm. -2000. -V.107. -P.815−829.
52. Sahin K., Stoeffler A., Fortuna P. Et al. Dementia severity and the magnitude of cognitive benifit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. //Neurobiol.Aging. -2000. -Vol.21.-P.S27.
53. Sarter M. Taking stock of cognitive enhancers. //Trends Pharm Sci. -1991. -V.12. -№ 12. -P.456−461.
54. Wilson R.S., A.W.Kasniak, J.H.Fox. Remote memory in senile dementia. //Cortex. -1981. -V.17. -P.41−48.